Table 4.

Association between MeDi score and annualized change in eGFR

MeDi ScoreParameter Estimate 
(95% CI)aP Value
Continuous (per 1-point increase in MeDi score)
 Unadjusted0.13 (0.01 to 0.24)0.03
 Demographic adjustedb0.09 (−0.02 to 0.21)0.12
 Fully adjustedc0.07 (−0.03 to 0.17)0.17
MeDi score ≥5 (versus <5)
 Unadjusted0.36 (−0.01 to 0.72)0.06
 Demographic adjustedb0.31 (−0.05 to 0.67)0.10
 Fully adjustedc0.31 (−0.01 to 0.64)0.06
MeDi quartiles (unadjusted)
 0–3Ref
 40.08 (−0.47 to 0.62)0.79
 50.30 (−0.25 to 0.85)0.28
 6–90.52 (−0.01 to 1.05)0.05
MeDi quartiles (demographic adjusted)
 0–3Ref
 4−0.11 (−0.66 to 0.43)0.68
 50.25 (−0.29 to 0.80)0.36
 6–90.34 (−0.19 to 0.87)0.21
MeDi quartiles (fully adjusted)
 0–3Ref
 4−0.37 (−0.86 to 0.12)0.13
 50.11 (−0.37 to 0.60)0.65
 6–90.20 (−0.28 to 0.67)0.42
  • a Parameter estimate data are presented as the reduced rate of decline in eGFR in ml/min per 1.73 m2 per year.

  • b Adjusted for age (years), sex, race/ethnicity (black, white, Hispanic, or other), education (high school completion versus not), and insurance status (Medicare/private insurance versus Medicaid/no insurance).

  • c Adjusted for age (years), sex, race/ethnicity (black, white, Hispanic, or other), education (high school completion versus not), insurance status (Medicare/private insurance versus Medicaid/no insurance), physical activity (any exercise versus not), BMI (kg/m2), diabetes (yes or no), smoking status (never, past, or current), hypertension (yes or no), LDL (mg/dl), HDL (mg/dl), baseline eGFR (ml/min per 1.73 m2), and ACE inhibitor/ARB usage (yes or no).